SIETES :: 91846 citas

Resultados de la búsqueda por CLOPIDOGREL REFINAR BÚSQUEDA

1.

Wang Y-F, Chen Y-T, Luo J-C, Chen T-J, Wu J-C, Wang S-J. Proton-pump inhibitor use and the risk of first-time ischemic stroke in the general population: a nationwide population-based study. The American Journal of Gastroenterology 2017:11 de abril. [Ref.ID 101543]

2.

Jolly SS, Natarajan MK. Atrial fibrillation and PCI - Do we still need aspirin?. N Engl J Med 2016;373:2490-2. [Ref.ID 101034]

3.

Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GYH, Cohen M, Husted S, Peterson ED, Fox KA. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016;373:2423-34. [Ref.ID 101032]

4.

Gargiulo G, Windecker S, da Costa BR, Feres F, Hong M-K, Gilard M, Kim H-S, Colombo A, Bhatt DL, Kim B-K, Morice M-C, Park KW, Chieffo A, Palmerini T, Stone GW, Valgimigli M. Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. BMJ 2016;355:i5483. [Ref.ID 100878]

5.

Anónimo. AstraZeneca says Brilinta failed to show PAD benefit over generic blood thinner. DIA Daily 2016:5. [Ref.ID 100778]

6.

Hankey GJ. The benefits of aspirin in early secondary stroke prevention. N Engl J Med 2016;388:312-4. [Ref.ID 100643]

7.

Johnston SC, Amarenco P, Albers GW, Denison H, Easton D, Evans SR, Held P, Jonasson J, Minematsu K, Molina CA, Wang Y, Wong KSL, for the SOCRATES Steering Committee and Investigators. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med 2016;375:35-43. [Ref.ID 100628]

8.

Wang Y, Zhao X, Lin J, Johnston C, Lin Y, Pan Y, Liu L, Wang D, Wang C, Meng X, Xu J, for the CHANCE Investigators. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA 2016;316:70-8. [Ref.ID 100516]

9.

Baharoglu M, Cordonnier C, Salman RAS, de Gans K, Koopman MM, Brand A, Majoie CB, Beenen LF, Marquering HA, Vermeulen M, Nederkoorn PJ, de Haan RJ, Roos YB, PATCH Investigators. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet 2016;387:2605-13. [Ref.ID 100468]

10.

Rothwell PM, Algra A, Chen Z, Diener H-C, Norrving B, Mehta Z. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet 2016;388:365-75. [Ref.ID 100282]

11.

Yeh RW, Secemsky EA, Kereiakes DJ, Normand S-LT, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L, for the DAPT Study Investigators. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA 2016;315:1735-49. [Ref.ID 100183]

12.

Kim H-S, Lim Y, Oh M, Ghim J-I, Kim E-Y, Kim DH, Shin J-G. The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes. Br J Clin Pharmacol 2016;81:301-12. [Ref.ID 100147]

13.

Ferro A. Newer antiplatelet agents in acute coronary syndrome. BMJ 2016;352:h7025. [Ref.ID 99965]

14.

Marciniak TA, Cherepanov V, Golukhova I, Hyun Kim M, Serebruany V. Drug discontinuation and follow-up rates in oral antithrombotic trials. JAMA Intern Med 2016;176:11 de enero. [Ref.ID 99961]

15.

Schoenfeld AJ, Grady D. Adverse effects associated with proton pump inhibitors. JAMA Intern Med 2016;176:febrero. [Ref.ID 99958]

16.

Voelker R. No increased risk of death with clopidogrel. JAMA 2015;314:2497. [Ref.ID 99759]

17.

Young K. Who might benefit from long-term DAPT? Risk score may help . Journal Watch 2015:1. [Ref.ID 99636]

18.

Olsen A-MS, Lindhardsen J, Gislason GH, McGettigan P, Hlatky MA, Fosbøl E, Køber L, Torp-Pedersen C, Lamberts M. Impact of proton pump inhibitor treatment on gastrointestinal bleeding associated with non-steroidal anti-inflammatory drug use among post-myocardial infarction patients taking antithrombotics: nationwide study. BMJ 2015;351:h5096. [Ref.ID 99631]

19.

Anónimo. FDA Drug Safety Communication: FDA review finds long-term treatment with blood-thinning medicine Plavix (clopidogrel) does not change risk of death. FDA U.S. Food and Drug Administration 2015:6 de noviembre. [Ref.ID 99630]

20.

Cressman AM, Macdonald EM, Fernandes KA, Gomes T, Paterson JM, Mamdani MM, Juurlink DN, for the Canadian Drug Safety Effectiveness Research Network (CDSERN). A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors. Br J Clin Pharmacol 2015;80:662-9. [Ref.ID 99608]